Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Otavio Berwanger and Remo Furtado.
Otavio Berwanger
Connection Strength
0.639
Remo Furtado
  1. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 09; 9(9):586-594.
    View in: PubMed
    Score: 0.239
  2. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020 10 03; 396(10256):959-967.
    View in: PubMed
    Score: 0.225
  3. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021 06 12; 397(10291):2253-2263.
    View in: PubMed
    Score: 0.059
  4. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial. Am Heart J. 2021 08; 238:1-11.
    View in: PubMed
    Score: 0.059
  5. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020 11 19; 383(21):2041-2052.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.